Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Zolmitriptan. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1D known ✓ | P28221 | 13/20 | 0.82 |
| ▸ | HTR1B known ✓ | P28222 | 13/20 | 0.82 |
| ▸ | HTR1A | P08908 | 9/20 | 0.82 |
| ▸ | HTR2A | P28223 | 5/20 | 0.82 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.82 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.82 |
| ▸ | HTR1F | P30939 | 2/20 | 0.72 |
| ▸ | HTR2B | P41595 | 2/20 | 0.72 |
| ▸ | HTR7 | P34969 | 2/20 | 0.72 |
| ▸ | HTR5A | P47898 | 2/20 | 0.72 |
| ▸ | HTR2C | P28335 | 2/20 | 0.72 |
| ▸ | HTR1E | P28566 | 1/20 | 0.72 |
| ▸ | HTR3A | P46098 | 1/20 | 0.72 |
| ▸ | SLC47A1 | Q96FL8 | 1/20 | 0.72 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.52 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.52 |
| ▸ | HTR6 | P50406 | 1/20 | 0.50 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Zolmitriptan SCHEMBL4427888 | 0.91 | HTR1D (1.00) | HTR1DHTR1BHTR1AHTR2AKMT2A | |
| Zolmitriptan SCHEMBL40595 | 0.91 | HTR1D (1.00) | HTR1DHTR1BHTR1AHTR2AKMT2A | |
| Zolmitriptan SCHEMBL1246512 | 0.91 | HTR1D (1.00) | HTR1DHTR1BHTR1AHTR2AKMT2A | |
| Zolmitriptan SCHEMBL14861150 | 0.91 | HTR1D (1.00) | HTR1DHTR1BHTR1AHTR2AKMT2A | |
| Zolmitriptan SCHEMBL29356689 | 0.91 | HTR1D (1.00) | HTR1DHTR1BHTR1AHTR2AKMT2A | |
| Zolmitriptan SCHEMBL33336 | 0.91 | HTR1D (1.00) | HTR1DHTR1BHTR1AHTR2AKMT2A | |
| Zolmitriptan SCHEMBL29835946 | 0.91 | HTR1D (1.00) | HTR1DHTR1BHTR1AHTR2AKMT2A | |
| Zolmitriptan SCHEMBL2458156 | 0.90 | HTR1D (0.98) | HTR1DHTR1BHTR1AHTR2AKMT2A | |
| Zolmitriptan SCHEMBL2377949 | 0.90 | HTR1D (0.98) | HTR1DHTR1BHTR1AHTR2AKMT2A | |
| Zolmitriptan SCHEMBL2540996 | 0.87 | HTR1D (0.92) | HTR1DHTR1BHTR1AHTR2AKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050101653-A1 | Combination therapy for the treatment of migraine | SANDS GEORGE H (US) | 2005-05-12 | — | — | US | claimed |
| US-20030216458-A1 | Combination therapy for the treatment of migraine | PFIZER INC. | 2003-11-20 | — | — | US | claimed |
| US-6476042-B1 | Combination therapy for the treatment of migraine | PFIZER INC. | 2002-11-05 | — | — | US | claimed |
| EP-1064948-A2 | Combination of an 5HT1 receptor antagonist, caffeine and a cyclooxygenase-2 inhibitor for the treatment of migraine | Pfizer Products Inc. (US) | 2001-01-03 | — | — | EP | claimed |
| EP-1064967-A2 | 5HT1 receptor agonists, caffeine and either a COX-2 inhibitor or NSAID for the treatment of migraine | Pfizer Products Inc. (US) | 2001-01-03 | — | — | EP | claimed |
| EP-1064966-A2 | Combination of an 5HT1 receptor antagonist, caffeine and a cyclooxygenase-2 inhibitor for the treatment of migraine | Pfizer Products Inc. (US) | 2001-01-03 | — | — | EP | claimed |
| EP-1051994-A2 | 5HT1 receptor agonists and a cox-2 inhibitor for the treatment of migraine | Pfizer Products Inc. (US) | 2000-11-15 | — | — | EP | claimed |
| EP-1051995-A2 | 5HT1 receptor agonists and a cox-2 inhibitor or NSAID for the treatment of migraine | Pfizer Products Inc. (US) | 2000-11-15 | — | — | EP | claimed |
| EP-1051993-A2 | 5HT1 receptor agonists and either a cox-2 inhibitor or NSAID for the treatment of migraine | Pfizer Products Inc. (US) | 2000-11-15 | — | — | EP | claimed |
| WO-2011124570-A2 | ORAL FILM FORMULATION | LABTEC GMBH (DE) | 2011-10-13 | — | — | WO | disclosed |
| EP-2374448-A1 | Oral film formulation | Labtec GmbH (DE) | 2011-10-12 | — | — | EP | disclosed |
| EP-1083918-A1 | NOVEL THERAPEUTIC AGENTS THAT MODULATE 5-HT RECEPTORS | Advanced Medicine, Inc. (US) | 2001-03-21 | — | — | EP | disclosed |
| WO-1999064044-A1 | NOVEL THERAPEUTIC AGENTS THAT MODULATE 5-HT RECEPTORS | ADVANCED MEDICINE, INC. (US) | 1999-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030216458-A1 | Combination therapy for the treatment of migraine | HTR1A, HTR2A, HTR2C | HTR1D 19/4885HTR1B 6/4885HTR1A 1/4885 |
| US-20050101653-A1 | Combination therapy for the treatment of migraine | HTR1A, HTR2A, HTR1B | HTR1D 13/4885HTR1B 3/4885HTR1A 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.